Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone
Gore Joins Vascular and Endovascular Leaders in Recognizing the 2016 Pioneers in Performance for North America
Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy
FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access
Flexibility and Durability to Aid Hemodialysis Patients
Gore REDUCE Clinical Study Completes Enrollment
Study of Closure of Patent Foramen Ovale (PFO) in Stroke Patients Reaches Major Milestone
Gore Recognized as one of the Worlds Best Multinational Workplaces by Great Place to Work®
Company earns No. 3 spot
Gore Joins Americas Hernia Society Quality Collaborative (AHSQC) as Silver Sponsor
Partnership latest step in Gore’s ongoing commitment to improve quality of care for hernia patients
GORE® EXCLUDER® Iliac Branch Endoprosthesis Gains FDA Approval
Gore designed all-in-one system to preserve iliac artery blood flow in patients with iliac or aortoiliac aneurysms
First Implant Completed in Thoracoabdominal Aortic Aneurysm Clinical Study
New investigative Gore device is designed to treat aortic aneurysms involving visceral branch vessels
GORE® EXCLUDER® Iliac Branch Endoprosthesis Exceeds 1,000 Implants Worldwide
Innovative system for managing common iliac artery aneurysms or aortoiliac aneurysms impacting lives around the world
GORE® C3 Delivery System Approved In Japan
System Enables Physicians and Interventionalists to Reposition GORE® EXCLUDER® AAA Endoprosthesis for Ideal Placement in Treating Abdominal Aortic Aneurysms